Invitae’s Common Hereditary Cancers panel is a first of its kind for the diagnostics industry.
On 29 September, the diagnostic received de novo authorization with special controls from the US Food and Drug Administration, opening the door for similar products to be cleared through...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?